Ellston, Rebecca
AstraZeneca (United Kingdom)
2 papers on CoChatORCID 0000-0003-3036-190X
Most cited papers
- Verified
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research
PI3K/AKT/mTOR signaling in cancerAutophagy in Disease and Therapy
Cited by 812
- Verified
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine
Protein Kinase Regulation and GTPase SignalingRNA Interference and Gene Delivery
Cited by 177
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free